Glaxo Seeks Approval for Tykerb for the Treatment of Advanced Breast Cancer
Breast Cancer Drug Tykerb
GlaxoSmithKline plc today announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for approval to market Tykerb
Share this content.
If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.